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Impact of Oxypurinol in
Patients With Symptomatic Heart Failure
Results of the OPT-CHF Study
Joshua M. Hare, MD,* Brian Mangal, MSC,† Joanne Brown, BSC,† Charles Fisher, JR, MD,†
Ronald Freudenberger, MD,‡ Wilson S. Colucci, MD,§ Douglas L. Mann, MD, Peter Liu, MD,¶
Michael M. Givertz, MD,# Richard P. Schwarz, PHD,* for the OPT-CHF Investigators
Miami, Florida; Vancouver, British Columbia and Toronto, Ontario, Canada; New Brunswick, New Jersey;
Boston, Massachusetts; and Houston, Texas
Objectives This study evaluated whether a xanthine oxidase (XO) inhibitor, oxypurinol, produces clinical benefits in patients
with New York Heart Association functional class III to IV heart failure due to systolic dysfunction receiving opti-
mal medical therapy.
Background Increased XO activity may contribute to heart failure pathophysiology.
Methods Patients (n  405) were randomized to oxypurinol (600 mg/day) or placebo. Efficacy at 24 weeks was assessed
using a composite end point comprising heart failure morbidity, mortality, and quality of life.
Results The percentage of patients characterized as improved, unchanged, or worsened did not differ between those
receiving oxypurinol or placebo. Oxypurinol reduced serum uric acid (SUA) by 2 mg/dl (p  0.001). In a sub-
group analysis, patients with elevated SUA (9.5 mg/dl, n  108) responded favorably to oxypurinol (p  0.02
for interaction term), whereas oxypurinol patients with SUA 9.5 mg/dl exhibited a trend towards worsening. In
addition, SUA reduction to oxypurinol correlated with favorable clinical response. Within the entire oxypurinol
patient cohort, those characterized as either improved or unchanged had significantly greater reductions in SUA
compared with patients who worsened (2.3  2.1 mg/dl vs. 1.0  1.9 mg/dl, p  0.0006). In placebo pa-
tients, lower baseline SUA, but not change in SUA, correlated with improved clinical outcome.
Conclusions Oxypurinol did not produce clinical improvements in unselected patients with moderate-to-severe heart failure.
However, post-hoc analysis suggests that benefits occur in patients with elevated SUA in a manner correlating
with the degree of SUA reduction. Serum uric acid may serve as a valuable biomarker to target XO inhibition in
heart failure. (Oxypurinol Compared With Placebo for Class III-IV NYHA Congestive Heart Failure; NCT00063687)
(J Am Coll Cardiol 2008;51:2301–9) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.01.068p
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plevation in the abundance and the enzymatic activity of
anthine oxidase (XO) is described in experimental animals
1–3) and humans (4,5) with heart failure. The up-
egulation of this pathway contributes to both vasoconstric-
ion and reduced myocardial function, which are hallmarks
f congestive heart failure (6). Enhanced activity of this
nzyme system may produce increases in oxidative stress and
evels of uric acid (7,8), both of which may contribute to the
rom *The University of Miami Miller School of Medicine, Miami, Florida;
Cardiome Pharma Corporation, Vancouver, British Columbia, Canada; ‡Robert
ood Johnson University Hospital, New Brunswick, New Jersey; §Boston Univer-
ity, Boston, Massachusetts; Baylor Heart Clinic, Houston, Texas; ¶Toronto
eneral Hospital, Toronto, Ontario, Canada; and #Brigham & Women’s Hospital,
oston, Massachusetts. This study was funded by Cardiome Pharma Corp., Vancouver,
ritish Columbia, Canada. Brian Mangal, Joanne Brown, and Dr. Fisher are employees
f Cardiome Pharma Corp. Dr. Hare is a consultant to Cardiome Pharma Corp.E
Manuscript received October 4, 2007; revised manuscript received January 2, 2008,
ccepted January 15, 2008.athophysiology of cardiovascular (CV) disease (9). Previ-
us studies have suggested that XO inhibition may improve
ndothelial reactivity (9), myocardial function (4), and
See page 2310
jection fraction (10) in patients with congestive heart
ailure. The purpose of this study was to test whether XO
nhibition would produce clinical benefits in patients with
ystolic dysfunction and symptomatic heart failure treated
ith a background of optimal heart failure therapies.
ethods
he design of this multicenter, randomized, double-blind,
lacebo-controlled, parallel group OPT-CHF study (The
fficacy and Safety Study of Oxypurinol Added to Standard
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Impact of Oxypurinol in HF Patients June 17, 2008:2301–9Therapy in Patients With New
York Heart Association Class
III-IV Congestive Heart Failure)
is described in detail elsewhere
(11).
Patients. Eligible patients were
between 18 to 85 years old, had
symptomatic heart failure (New
York Heart Association [NYHA]
functional class III to IV), and
left ventricular dysfunction de-
fined as a left ventricular ejection
fraction 40%. Patients were
eligible if they had at least 1
hospitalization for heart failure
within 18 months, an emergency
room visit resulting in treatment
with intravenous therapy for
worsening heart failure, or if a
new drug class for heart failure
as added to their regimen due to lack of medical stability.
atients receiving continuous or intermittent intravenous
notropic or vasodilator agents for a period of at least 4
eeks before entering the study in any dosage (varying
osages allowed) met the criteria for new drug therapy
ddition. Investigators were asked to ensure each patient
as, in their opinion, on an optimum dose of heart failure
edication, a requirement for study entry.
tudy design. Patients were randomized to oxypurinol or
lacebo. The initial dose for both active and placebo groups
uring the first week post-randomization was 1 capsule (100
g oxypurinol or matching placebo). Subsequently, both
roups received 6 capsules (600 mg) daily. Patients with
educed renal function had their study medication titrated
ased on serum creatinine levels, and those with creatinine
3.0 were excluded (11).
Study drug was initiated after a 2-week run-in period,
uring which time stability of symptoms and background
reatment were assessed and baseline assessments were
btained. Patients were monitored with outpatient visits
very 4 weeks for 24 weeks, at which time they received a
istory and physical examination, NYHA functional class
ssessment, a 6-min walk test, the Patient Global Assess-
ent of Heart Failure questionnaire, and the Minnesota
iving with Heart Failure (MLHF) questionnaire (a
uality-of-life assessment).
Patients remained on their assigned dosage until the end
f the study, unless the investigator felt an adverse event was
rug related and required drug withdrawal, or the patient
ithdrew consent to continue on study medication. These
atients were followed as part of the intent-to-treat (ITT)
ohort, and received all protocol-related study procedures
hrough the 24-week time point. Patients who did not
eturn for study procedures after study drug withdrawal
Abbreviations
and Acronyms
BNP  brain natriuretic
peptide
CCE  composite clinical
end point
CI  confidence interval
CV  cardiovascular
ITT  intent to treat
MLHF  Minnesota Living
with Heart Failure
NYHA  New York Heart
Association
PGHFCS  Patient Global
Heart Failure Clinical
Status
SUA  serum uric acid
XO  xanthine oxidaseere contacted at the conclusion of the trial to determine wheir mortality status, unless they formally withdrew consent
o participate in the study.
tudy end points. The primary end point was a composite
linical end point (CCE) that classified subject’s clinical
tatus as improved, worsened, or unchanged at week 24,
imilar to that reported in Packer (12), with a slight
odification. The classification followed sequential rules
ased on the outcomes of the following items: 1) CV death;
) hospitalization, emergency room, or emergent office/
linic visit for worsening heart failure; 3) administration of
new drug class for heart failure or the administration of
ntravenous diuretics de novo for worsening heart failure;
) permanent withdrawal of study drug due to worsening
eart failure; 5) NYHA functional class; or 6) Patient
lobal Heart Failure Clinical Status (PGHFCS). These
omponents were adjudicated by a clinical events commit-
ee. A patient was classified as worsened if they died, were
ospitalized, visited an emergency room, or experienced an
mergent office or clinic visit adjudicated by the clinical
vents committee to be primarily for treatment of worsening
eart failure symptoms. In addition, worsening was defined
y a decrement in NYHA functional class at week 24, a
GHFCS assessment at week 24 in which the patient
ndicated moderately or markedly worse symptoms of heart
ailure, the addition of a new drug class for heart failure, the
dministration of intravenous diuretics de novo for worsen-
ng heart failure, or permanent discontinuation from study
edication due to worsening heart failure. With regards to
ddition of a new class of drugs, substituting one class for
nother due to a side effect (e.g., angiotensin receptor
locker for angiotensin-converting enzyme inhibitor) did
ot constitute this end point. A patient was characterized as
mproved if none of the above occurred and they improved
ne or more NYHA functional classes, or if they indicated
moderate or marked improvement in the PGHFCS
ssessment. Patients who met criteria for neither improving
or worsening were classified as unchanged. Patients were
valuated on an ITT basis.
Secondary efficacy end points included time to first
ccurrence of CV death or hospitalization for worsening
eart failure; change from baseline to week 24 in quality-of-life
core as assessed by the MLHF questionnaire, and change
rom baseline to week 24 in serum uric acid (SUA) levels.
ertiary end points included individual components of the
CE in addition to the 6-min walk test, and the time to
ll-cause death and all-cause hospitalization.
The study was approved by institutional review boards at
ll participating centers, and all patients gave written in-
ormed consent. Four hundred and five patients were
nrolled between March 2003 and December 2004 at 54
enters in Canada and the U.S. Of the 405 randomized
atients, 51 patients did not complete the study through to
he 24-week visit, 22 withdrew consent, 15 died, and 14
iscontinued for other reasons. Where possible, every effort
as made to determine the 24-week status of all patients
ho withdrew from the study.
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June 17, 2008:2301–9 Impact of Oxypurinol in HF Patientsubgroup analysis. An additional exploratory analysis was
onducted to examine the effect of SUA on the primary
CE outcome. Patients were classified as high SUA if they
ad a baseline SUA 9.5 mg/dl, and low SUA if they had
baseline SUA 9.5 mg/dl, which was a cutoff chosen
ased on previously published findings (7). In addition, the
egree of SUA reduction was assessed within these
ubgroups.
tatistical methods. All analyses were conducted using
he ITT principle. Analysis of the primary efficacy CCE
nd point utilized the Cochran-Mantel-Haenszel mean
core test with modified ridit scores to compare the
istributions. Patients who were lost to follow-up were
valuated for all end points using the last value carried
orward method. The same approach was applied to the
nalysis of the change from baseline in NYHA functional
aseline Characteristics
Table 1 Baseline Characteristics
Placebo
(n  202)
Oxypurinol
(n  203)
Age, yrs (mean  SD) 65  13 64  13
Male gender (%) 70 76
Race (%)
Caucasian 80 75
Black 15 20
NYHA functional class III (%) 96 96
LVEF (mean  SD) 27.7  13.4 25.3  13.1
6MWT (m) 278  123 257  118
Medication use (%)
Diuretics 95 95
ACE inhibitor 75 72
ARB 19 25
Beta-blocker 90 93
Carvedilol 83 84
Digoxin 56 54
Spironolactone 34 36
Nitrates 33 33
Etiology (%)
Ischemic 60.9 61.1
Idiopathic 22.8 20.2
Hypertensive 5.9 7.4
Entry criteria (%)
Hospitalized 69.8 68.3
ER visit 24.3 25.2
New HF medication 44.8 45.2
On maximum tolerated medications (%) 99.0 99.5
Median (25th to 75th quartile) SUA
(mg/dl)
Overall 7.8 (6.4–9.2) 7.9 (6.4–9.8)
SUA 9.5 7.1 (5.9–8.3) 7.0 (6.0–8.0)
SUA 9.5 10.6 (9.9–11.6) 11.4 (10.3–12.5)
Mean (25th to 75th quartile) BNP
(pg/ml)
Overall 186 (73–402) 234 (81–464)
SUA 9.5 177 (68–403) 187 (66–422)
SUA 9.5 225 (80–392) 326 (140–564)
CE  angiotensin-converting enzyme; ARB  angiotensin receptor blocker; BNP  brain natri-
retic peptide; ER emergency room; HF heart failure; LVEF left ventricular ejection fraction;
YHA  New York Heart Association; SUA  serum uric acid; 6MWT  6-min walk test. olass, where subjects were classified as improved by 2 or
ore categories, improved by 1 category, unchanged, or
orsened by 1 category, and the PGHFCS assessment at
eek 24. Analyses of the time-to-event end points
tilized the log-rank test to compare distributions be-
ween treatment groups, and a Cox proportional hazards
egression model for estimation of the hazard ratios.
nalysis of the change from baseline in SUA, MLHF
uestionnaire score, and the 6-min walk test score was
onducted using a repeated measures mixed model, with
aseline score as a covariate and treatment, time, and the
reatment by time interaction as fixed effects. For the
LHF questionnaire score and the 6-min walk test,
he covariance matrix was specified to be autoregressive of
rder one, while for SUA an unstructured covariance matrix
as used. The choice of covariance matrix was examined.
xamination of the strength of an association between the
Figure 1 Impact of Oxypurinol on the CCE
As depicted, randomization to oxypurinol failed to increase the proportion of
patients improving according to the composite categorization. CCE  compos-
ite clinical end point.
omponents of Primary End Point (ITT Population)
Table 2 Components of Primary End Point (ITT Population)
Placebo
(n  202)
Oxypurinol
(n  203) p Value
Improved 91 (45.0%) 88 (43.3%) 0.4211
NYHA and PGHFCS improved 28 35
NYHA improved 36 22
PGHFCS improved 27 31
Unchanged 72 (35.6%) 65 (32.0%)
NYHA and PGHFCS unchanged 72 65
Worsened 39 (19.3%) 50 (24.6%)
CV death 4 8
Hospitalization/ER/office visit for HF 18 29
Use of new medication for HF 3 1
Discontinuation due to HF — 1
NYHA worsened — 1
PGHFCS worsened 7 4
Lost to follow-up 7 6
he components were derived based on the sequence as outlined in the Results section.
CV cardiovascular; ITT intent to treat; PGHFCS Patient Global Heart Failure Clinical Status;
ther abbreviations as in Table 1.
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Impact of Oxypurinol in HF Patients June 17, 2008:2301–9rimary end point and both SUA and brain natriuretic
eptide (BNP), as well as between BNP and SUA were
onducted using Pearson’s correlation test. Brain natriuretic
eptide was log transformed for these analyses. All analyses
ere conducted using SAS version 8.2 (SAS Institute, Cary,
orth Carolina).
esults
able 1 depicts the baseline characteristics of patients
nrolled in this study. Both groups were comparable across
ll baseline characteristics. The majority of patients were
YHA functional class III (96%), and virtually all patients
99%) were on maximum tolerated medications for their
eart failure.
rimary and secondary study outcomes. The distribution
f patients characterized as improved, worsened, and
nchanged as assessed by the primary composite end
oint did not differ between oxypurinol and placebo
roups (Fig. 1, Table 2). Improvement was observed in
1 (45%) subjects versus 88 (43%) subjects in the placebo
ersus oxypurinol groups, respectively; no change was
een in 72 (36%) versus 65 (32%) subjects, respectively,
nd worsening was seen in 39 (19%) versus 50 (25%)
econdary and Tertiary Clinical Events
Table 3 Secondary and Tertiary Clinical Events
Placebo
(n  202)
Oxypurinol
(n  203)
Hazard Ratio
(95% CI)* p Value†
Secondary end points
All-cause death 6 (3%) 10 (5%) 1.7 (0.6–4.7) 0.2906
CV death 4 (2%) 8 (4%) 2.1 (0.6–6.9) 0.2267
All-cause hospitalization 50 (25%) 59 (29%) 1.2 (0.8–1.7) 0.3405
HF hospitalization 15 (8%) 26 (13%) 1.8 (0.9–3.3) 0.0763
Tertiary end points
CV death/HF
hospitalization
18 (9%) 31 (15%) 1.8 (1.0–3.1) 0.0546
ER/office visit (HF) 4 (2%) 8 (4%) 2.0 (0.6–6.7) 0.2426
Based on a Cox proportional hazards model with the time to event as the end point; †based on a
og-rank test with time to event as the end point.
CI  confidence interval; HF  heart failure; other abbreviations as in Tables 1 and 2.
uality of Life and Clinical Status Outcomes
Table 4 Quality of Life and Clinical Status Outcomes
End Point Categorical Response
Change from baseline to week 24
in NYHA functional class
Improved by 2 or more categories
Improved by 1 category
Unchanged
Worsened by 1 category
Week 24 PGHFCS Markedly improved
Moderately improved
Mildly improved
No change
Slightly worse
Moderately worse
Markedly worsep value was calculated using a Cochran-Mantel-Haenszel mean score test.
NYHA  New York Heart Association; PGHFCS  Patient Global Heart Failure Clinical Status.ubjects in the placebo versus oxypurinol groups, respec-
ively (p  0.4211).
Table 3 depicts hazard ratios for secondary and tertiary
utcome measures. The majority of secondary and tertiary
vents, including all-cause or CV mortality, were not
ifferent between treatment groups. With regard to CV
eath or hospitalization for heart failure, 31 (15%)
xypurinol-treated patients and 18 (9%) placebo patients
xperienced this combined end point, with a trend towards
n increased risk (hazard ratio 1.8; 95% confidence interval
CI] 1.0 to 3.1, p  0.055) in oxypurinol-treated patients.
uality of life. The change from baseline to week 24 in the
LHF score was not different in placebo (4.3) and
xypurinol (5.6) groups. Change from baseline to week 24
n the NYHA functional class, and the PGHFCS assess-
ent at week 24, both components of the primary compos-
te end point, were comparable between treatment groups
Table 4). Finally, the change from baseline in the 6-min
alk test was also not different between treatment groups.
UA subgroup analysis. Oxypurinol produced a signifi-
ant reduction in SUA after 1 month of therapy, which was
aintained through to the end of the trial (Fig. 2). One of
he postulated mechanisms of oxypurinol benefit is to
nhibit uric acid production. Thus, we examined the impact
f the drug in groups of patients dichotomized by high or
ow SUA using 9.5 mg/dl as a cutoff. Using this cutoff, 108
21%) of the 405 patients were characterized as high SUA
atients: 60 in the oxypurinol group and 48 in the placebo
roup (Table 5).
Analysis of the primary CCE in the 2 SUA subgroups
evealed a significant subgroup by treatment interaction
p  0.02), indicating that the direction of the response
iffers within the subgroups (Fig. 3). In the subgroup of
atients with a high baseline SUA, there was a trend
owards benefit in the oxypurinol group: 31 (52%) versus 16
33%) improved, 16 (27%) versus 20 (42%) remained
nchanged, and 13 (22%) versus 12 (25%) worsened in the
xypurinol and placebo groups, respectively (Table 5). In
ontrast, analysis of the low baseline subgroup of patients
Placebo (n  202) Oxypurinol (n  203) p Value*
6 (3.3%) 2 (1.1%) 0.4
61 (33.7%) 54 (32.6%)
112 (61.9%) 113 (64.6%)
2 (1.1%) 3 (1.7%)
18 (10.0%) 24 (14.0%) 0.4
43 (23.9%) 44 (25.7%)
49 (27.2%) 39 (22.8%)
58 (32.2%) 51 (29.8%)
4 (2.2%) 8 (4.7%)
6 (3.3%) 4 (2.3%)
2 (1.1%) 1 (0.6%)
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June 17, 2008:2301–9 Impact of Oxypurinol in HF Patientsuggested worse outcomes due to oxypurinol: 57 (40%)
ersus 74 (49%) improved, 48 (33%) versus 51 (33%)
emained unchanged, and 37 (26%) versus 27 (18%) wors-
ned in the oxypurinol and placebo groups, respectively
Table 5).
Table 6 depicts the secondary and tertiary outcome
easures in the 2 SUA subgroups. Oxypurinol-treated
atients with a baseline SUA 9.5 mg/dl showed a trend
owards decreased risk for all-cause (hazard ratio 0.4; 95%
I 0.1 to 2.1) and CV (hazard ratio 0.5; 95% CI 0.1 to 3)
eath compared with placebo-treated patients. A similar
rend was not seen in oxypurinol patients with an SUA
9.5 mg/dl.
Figure 2 Impact of Oxypurinol on SUA
Serum uric acid (SUA) was measured at monthly intervals throughout the
6-month follow-up period. As depicted, oxypurinol effectively lowered SUA by
approximately 2 mg/dl, and this effect was evident within 1 month of therapy.
*Indicates p  0.0001 versus placebo and is based on a repeated measures
mixed model with baseline as a covariate and change from baseline as the
dependent variable.
omponents of the Primary End Point Within SUA Subgroups (ITT P
Table 5 Components of the Primary End Point Within SUA Subg
SUA >9.5 m
Placebo
(n  48)
Oxypurin
(n  60
Improved 16 (33%) 31 (52%
NYHA and PGHFCS improved 7 9
NYHA improved 4 6
PGHFCS improved 5 16
Unchanged 20 (42%) 16 (27%
NYHA and PGHFCS unchanged 20 16
Worsened 12 (25%) 13 (22%
CV death 3 2
Hospitalization/ER/office visit for HF 3 9
Use of new medication for HF — —
Discontinuation due to HF — —
NYHA worsened — 1
PGHFCS worsened 3 —
Lost to follow-up 3 1bbreviations as in Tables 1 and 2.uality of life. Although the change from baseline to week
4 NYHA functional class was no different in the SUA
ubgroup analysis, the baseline to week 24 PGHFCS end
oint indicated that oxypurinol-treated patients with a
aseline SUA 9.5 mg/dl had statistically significant im-
Figure 3 Impact of Oxypurinol on the
CCE in High and Low SUA Subgroups
p  0.02 for interaction between high and low serum
uric acid (SUA) groups. CCE  composite clinical end point.
ation)
s (ITT Population)
SUA <9.5 mg/dl
p Value
Placebo
(n  152)
Oxypurinol
(n  142) p Value
0.1270 74 (49%) 57 (40%) 0.0720
21 26
31 16
22 15
51 (33%) 48 (33%)
51 48
27 (18%) 37 (26%)
1 6
15 20
3 1
— 1
— —
4 4
4 5opul
roup
g/dl
ol
)
)
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Impact of Oxypurinol in HF Patients June 17, 2008:2301–9rovements compared with placebo-treated patients (p 
.02); a driving force behind the trend seen in the CCE.
xypurinol patients with baseline SUA levels 9.5 mg/dl
id not exhibit in a similar trend (Table 7).
Evaluation of baseline SUA levels in the placebo group
upported the notion that increasing levels of SUA corre-
pond with worsening outcome (Table 8). Interestingly, this
attern was not observed in the oxypurinol group, consistent
ith a treatment response to the drug linked to its impact
n SUA.
Within the entire oxypurinol cohort, there was an asso-
iation between improvement and reduction in SUA (r 
.23; p  0.0014). Patients who improved had an average
eduction in SUA of 2.3  2.1 mg/dl, patients who
emained unchanged had an average reduction in SUA of
.2 2.0 mg/dl, and patients who worsened had an average
eduction in SUA of 1.0  1.9 mg/dl. Figure 4 shows a
catter plot of the baseline and final SUA measurements by
reatment group and response. In addition, in the entire
Secondary and Tertiary Clinical Events by SUA S
Table 6 Secondary and Tertiary Clinical Eve
Baseline SUA (mg/dl
Secondary end point
CV death/HF hospitalization 9.5
9.5
Tertiary end points
All-cause death 9.5
9.5
CV death 9.5
9.5
All-cause hospitalization 9.5
9.5
HF hospitalization 9.5
9.5
ER/office visit (HF) 9.5
9.5
CI  confidence interval; other abbreviations as in Tables 1 and 2.
uality of Life and Clinical Status Outcome by SUA Subgroup (ITT P
Table 7 Quality of Life and Clinical Status Outcome by SUA Su
End Point
S
Placebo
(n  48)
Change from baseline to week 24 in NYHA functional class
Improved by 2 or more categories 2 (4%)
Improved by 1 category 9 (19%)
Unchanged 36 (75%)
Worsened by 1 category 1 (2%)
Week 24 PGHFCS
Markedly improved 2 (4%)
Moderately improved 11 (23%)
Mildly improved 14 (29%)
No change 14 (29%)
Slightly worse 3 (6%)
Moderately worse 2 (4%)
Markedly worse 2 (4%)bbreviations as in Tables 1 and 2.ohort of oxypurinol-treated patients, those experiencing
eath or hospitalization had lower degrees of SUA reduc-
ion (0.9 vs. 2.1, p  0.0026). Within the oxypurinol
igh SUA subgroup, patients who improved had an average
UA decrease of 3.5 mg/dl compared with 1.7 mg/dl in the
atients categorized as worsened (Fig. 5).
elationship between SUA and BNP. There was a rela-
ionship between the natural logarithm of baseline BNP and
aseline SUA (r  0.11; p  0.0351); however, no rela-
ionship between change in SUA and change in BNP was
een (r  0.03; p  0.6676 for oxypurinol group and r 
0.08; p  0.2466 for placebo). Evaluation of an associa-
ion between outcome and baseline BNP levels in the
xypurinol and placebo groups showed a significant associ-
tion between baseline BNP and outcome in the oxypurinol
roup but not in the placebo group (Table 8). When
valuated based on the change from baseline by CCE
utcome, both oxypurinol and placebo-treated patient BNP
alues decreased with improved outcomes (Table 9).
oup (ITT Population)
y SUA Subgroup (ITT Population)
Placebo Oxypurinol Hazard Ratio (95% CI)
13 (9%) 20 (14%) 1.7 (0.6–4.6)
5 (10%) 11 (18%) 1.7 (0.9–3.5)
2 (1%) 8 (6%) 4.5 (1.0–21.3)
4 (8%) 2 (3%) 0.4 (0.1–2.1)
1 (1%) 6 (4%) 6.8 (0.8–55.6)
3 (6%) 2 (3%) 0.5 (0.1–3.1)
37 (24%) 37 (26%) 1.1 (0.7–1.7)
12 (25%) 22 (37%) 1.5 (0.7–3.0)
12 (8%) 17 (12%) 1.6 (0.9–3.3)
3 (6.3%) 9 (15%) 2.4 (0.6–8.7)
3 (2%) 8 (6%) 2.9 (0.8–11.0)
1 (2%) — —
ation)
p (ITT Population)
.5 mg/dl SUA <9.5 mg/dl
purinol
 60) p Value
Placebo
(n  152)
Oxypurinol
(n  142) p Value
— 0.9318 4 (3%) 2 (1%) 0.3587
(27%) 54 (36%) 44 (31%)
(67%) 92 (61%) 96 (68%)
(7%) 2 (1%) —
(8%) 0.0166 17 (11%) 20 (14%) 0.4869
(38%) 35 (23%) 27 (19%)
(28%) 38 (25%) 29 (20%)
(18%) 54 (36%) 53 (37%)
(5%) 3 (2%) 6 (4%)
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he OPT-CHF study was designed to test the hypothesis
hat inhibition of XO with oxypurinol, when added to best
onventional therapy, would improve clinical outcomes in
atients with symptomatic heart failure due to systolic
ysfunction. In this study, patients receiving active therapy
id not differ according to the primary outcome composite
easure relative to patients randomized to placebo. Accord-
aseline SUA and BNP Values
Table 8 Baseline SUA and BNP Values
Placebo Oxypurinol
SUA
Improved 7.6 1.95, r 0.15 8.4 2.68, r0.05
Unchanged 8.0 2.57 (p 0.0344) 8.2 2.44 (p 0.5308)
Worsened 8.6 2.46 8.1 2.59
BNP
Improved 5.2 1.2, r 0.07 5.0 1.2, r 0.15
Unchanged 4.9 1.3 (p 0.3066) 5.1 1.3 (p 0.0410)
Worsened 5.3 1.2 5.6 1.3
ata are reported as mean  SD. r is the Pearson correlation coefficient and brain natriuretic
eptide (BNP) is reported as the natural log.
SUA  serum uric acid.
Figure 4 Scatterplot of Baseline
SUA to Final SUA by Outcome
Overall, the oxypurinol-treated group had improved final serum uric acid (SUA)
compared with their baseline SUA levels when evaluated against the placebo
group. pngly, the study failed to achieve its primary end point.
mportantly, when dichotomized by SUA levels, using
.5 mg/dl as a cutoff, several lines of evidence support the
dea that heart failure patients with elevated SUA repre-
ent a patient population responsive to therapy with XO
nhibition.
Examination of secondary and tertiary end points showed
ittle to no impact of oxypurinol therapy. The combined end
oint of time to CV death plus heart failure hospitalization
uggested the possibility of an adverse response to oxypuri-
ol (Table 2). This finding argues against the use of
xypurinol in all patients with symptomatic heart failure due
o systolic dysfunction, and prompted an examination of
redictors of outcome within the study population.
Subgroup analysis demonstrated that patients with
levated levels of SUA may represent a responsive pop-
lation. The SUA findings are consistent with a series of
eports indicating that elevated SUA is a valuable bi-
marker of morbidity and mortality in heart failure (8).
nker et al. (7) proposed a cutoff of 9.5 mg/dl based on
n analysis of several populations. In the latter analysis,
sing a cross-sectional study design, high uric acid was
emonstrated to be associated with higher mortality and
reater need for cardiac transplantation. Importantly, in
he present study, the change in SUA response also
orrelated with clinical outcome. First, in the placebo
roup, SUA did not change over the 6-month period of
Figure 5 Degree of SUA Reduction in
Patients With Low and High SUA
As depicted, the degree of serum uric acid (SUA) reduction was greatest in
treated patients classified as improved or unchanged with high baseline SUA.
p  0.05 versus worsened group.
hange From Baseline BNP by CCE Outcome
Table 9 Change From Baseline BNP by CCE Outcome
Placebo Oxypurinol
Improved 0.24 0.83, r 0.17 0.30 0.84, r 0.05
Unchanged 0.09 0.67 (p 0.0125) 0.14 0.74 (p 0.4828)
Worsened 0.03 0.54 0.03 0.51
ata are reported as mean  SD; r is the Pearson correlation coefficient, and brain natriuretic
eptide (BNP) is reported as the natural log.
CCE  composite clinical end point.
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nd, in both the entire cohort and the high SUA group,
atients who worsened had substantially lower reductions
n SUA compared with the other groups. Finally, when
elevant secondary or tertiary end points were examined,
 failure to decrease SUA correlated with adverse out-
ome. Together, these analyses strongly suggest that an
ttenuated response to oxypurinol, as indicated by dimin-
shed SUA reduction, predicts failure of clinical response
nd possibly adverse outcomes.
Whether uric acid is toxic, per se, or is a biomarker of
anthine oxidoreductase activity is currently unclear.
nterestingly, most mammalian species have low circulat-
ng uric acid due to the presence of uricase, an enzyme
nactive in humans, which degrades uric acid (13).
evertheless, cardiac injury is associated with increased
O activity in many animal models, and one in particular
emonstrated the association between XO activity and
ric acid in myocardial tissue (14). Collectively, numer-
us animal models and human studies demonstrate im-
roved cardiac remodeling (3,15), cardiac energetics
16,17), endothelial function (5,9,18,19), and survival
fter cardiac injury (1,20) in response to XO inhibition.
ost recently, George et al. (21) argued against direct
oxicity of uric acid, and have demonstrated that the
bility of allopurinol to improve endothelial function
annot be attributed to uric acid lowering, per se (21).
ogether, these experimental and clinical studies suggest
hat uric acid may represent a valuable biomarker of XO
ctivity in the CV system. Indeed, the fact that approx-
mately one-quarter of the patients in this study had
evels of SUA above 9.5 mg/dl argues that this pathway is
ot addressed by other conventional medications, and
epresents an unaddressed therapeutic target in a substan-
ial proportion of patients. With regard to usage as a
iomarker, it is interesting to note that here we confirm
ur previous finding that SUA only weakly correlates
ith the logarithm of BNP and thus may offer additive
linical information (22).
There are several reasons why oxypurinol may not have
ed to clinical benefits in the broad population of symp-
omatic, treated patients. First, it is possible that sources
f oxidative stress are already inhibited by other medica-
ions such as inhibitors of the renin-angiotensin-
ldosterone pathway or carvedilol. In this regard, angio-
ensin II can activate XO directly (23) and indirectly via
ADPH oxidase (24). However, it may be argued that
atients with high SUA who did not respond to oxypuri-
ol and worsened did so due to lack of efficacy of the
edication. Indeed, in this cohort the level of SUA
eduction was substantially and significantly less com-
ared with that in patients with high SUA who remained
nchanged or who clinically improved. Moreover, find-
ngs from retrospective analyses have previously sug-
ested that patients receiving low-dose XO inhibitorsay worsen, whereas those receiving high doses may have
ortality and hospitalization reductions (25).
Although the post-hoc analysis of SUA is provocative,
t is limited. This was not a pre-specified analysis, and the
umbers of patients in the high SUA group were small.
hese results, however, are hypothesis generating, and
ffer potential explanations for why a hypothesis that was
o well supported by pre-clinical work failed to be borne
ut in humans with advanced heart failure. Future clinical
rials are required to prospectively assess the impact of
O inhibition in patients with high SUA.
onclusions
n summary, this study demonstrates that oxypurinol did
ot improve a clinical composite score in patients with
ystolic, symptomatic heart failure, and could potentially
ause harm to some patients. Subgroup analysis supports the
oncept that patients with these clinical characteristics and
high SUA may benefit from XO inhibition. Moreover, the
egree of SUA reduction correlated with clinical outcome,
uch that patients who worsened despite oxypurinol therapy
ad relatively less reduction in uric acid. Measurements of
ric acid may aid in individualizing therapy with XO
nhibitors.
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